To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Weiss, Mia C.; Eulo, Vanessa; Van Tine, Brian A.

doi:10.1158/1078-0432.CCR-23-2787

Article navigation

CCR Translations| February 16 2024

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Mia C. Weiss

0000-0002-8457-0523

;

Mia C. Weiss

1Washington University in St. Louis, School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, Missouri.

2Siteman Cancer Center, St. Louis, Missouri.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Vanessa Eulo

0000-0003-2304-2222

;

Vanessa Eulo

3Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Brian A. Van Tine

0000-0003-4572-6668

Brian A. Van Tine *

1Washington University in St. Louis, School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, Missouri.

2Siteman Cancer Center, St. Louis, Missouri.

4Department of Pediatric Hematology/Oncology, St. Louis Children's Hospital, St Louis, Missouri.

*Corresponding Author: Brian A. Van Tine, Professor of Medicine and Pediatrics, Division of Medical Oncology, Washington University in St. Louis, 660 South Euclid, Campus Box 8007, St. Louis, MO 63110. E-mail: [email protected]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Author & Article Information

*Corresponding Author: Brian A. Van Tine, Professor of Medicine and Pediatrics, Division of Medical Oncology, Washington University in St. Louis, 660 South Euclid, Campus Box 8007, St. Louis, MO 63110. E-mail: [email protected]

Clin Cancer Res 2024;30:649–51

Received: October 10 2023

Revision Received: November 14 2023

Accepted: November 28 2023

Online ISSN: 1557-3265

Print ISSN: 1078-0432

2023

American Association for Cancer Research

Clin Cancer Res (2024) 30 (4): 649–651.

https://doi.org/10.1158/1078-0432.CCR-23-2787

Summary

Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient's response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Summary

Citing articles via

Email alerts

AACR Journals

To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma

Summary

Sign in

Client Account

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only